

Astellas Announces Personnel Changes and Organization Changes

Tokyo, Japan, February 5, 2015 - Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Yoshihiko Hatanaka) announced the personnel changes and organization changes as below.

1. Appointment of Senior Corporate Executive of Astellas Pharma Inc. effective on April 1, 2015

Name	New Title	Current Title
Masaru Imahori	CEO's Office	Vice President, External Relations

2. Appointment of Corporate Executive of Astellas Pharma Inc. effective on April 1, 2015

Name	New Title	Current Title
Hirofumi Seki	CEO's Office	Divisional Senior Vice President, Technology Planning & Administration, Technology
Yoshihiro Minami	CEO's Office	General Marketing Compliance Officer(Japan)
Kenji Sumi	CEO's Office	General Manager, Tokyo Branch, Japan Sales & Marketing
Chihiro Yokota	Head of Japan/Asia Development, Global Development, and Head of Japan Medical Affairs	Head of Japan/Asia Development, Global Development
Makoto Takeuchi	Vice President, External Relations	Divisional Senior Vice President, Research Administration, Drug Discovery Research

3. Resignation of Senior Corporate Executive of Astellas Pharma Inc. effective on June 17, 2015

Name	Title (effective on April 1, 2015)
Masaru Imahori	CEO's Office

4. Resignation of Corporate Executive of Astellas Pharma Inc. effective on June 17, 2015

Name	Title (effective on April 1, 2015)
Hirofumi Seki	CEO's Office
Yoshihiro Minami	CEO's Office
Kenji Sumi	CEO's Office

5. Appointment of Senior Corporate Executive of Astellas Pharma Inc. effective on June 17, 2015

Name	Title (effective on April 1, 2015)
Mitsunori Matsuda	President, Technology
Yukihiko Sato	President, Japan Sales & Marketing
Chihiro Yokota	Head of Japan/Asia Development, Global Development, and Head of Japan Medical Affairs
Wataru Uchida	President, Drug Discovery Research
Makoto Takeuchi	Vice President, External Relations

6. New Corporate Executive of Astellas Pharma Inc. effective on June 17, 2015

Name	Title (effective on April 1, 2015)
Katsumi Ozawa	General Manager, Tokyo Branch, Japan Sales & Marketing
Kazuhiro Sako	President, Astellas Ireland Co., Ltd
Yukio Matsui	Senior Vice President, Global Marketing Strategy
Nobuaki Tanaka	General Manager, Chiba Branch, Japan Sales & Marketing
Toru Yoshimitsu	Corporate Vice President, Product and Portfolio Strategy
Eisuke Nozawa	Vice President, Regulatory Affairs-Japan, Global Regulatory Affairs
Fumiaki Sakurai	Corporate Vice President, Human Resources
Taiji Sawamoto	Vice President, Clinical Pharmacology, Global Development

7. Personnel Changes of Astellas Pharma Inc. effective on April 1, 2015

Name	New Title	Current Title
Shigeki Kawabata	Vice President, Evolving Medical Solutions	Vice President, Pharma Breakthrough
Masaaki Usui	Vice President, Corporate Communications	President, Astellas Pharma Australia Pty Ltd
Shinya Suda	Corporate Vice President, Information Systems (No change: only Japanese organization name will be changed)	Corporate Vice President, Information Systems
Noriyuki Masuda	Divisional Senior Vice President, Research Administration, DDR	Executive Director, Research Portfolio & Science, Drug Discovery Research
Minori Saitoh	Vice President, Drug Repurposing & Application Management	Senior Director, Research Portfolio & Science, Drug Discovery Research
Tomonobu Koizumi	Vice President, Regenerative Medicine Labs., Drug Discovery Research	Vice President, Bioscience Research Labs., Drug Discovery Research
Rika Hirota	Vice President, Bioscience Research Labs., Drug Discovery Research	Senior Director, Drug Safety Research Labs., Drug Discovery Research
Shigeki Tanaka	Vice President, Japan/Asia Clinical Development 1, Japan/Asia Development	Vice President, Asian Development, Development
Toshiyuki Sueyoshi	Vice President, Japan/Asia Clinical Development 2, Japan/Asia Development	Vice President, Clinical Development 2, Development
Takuya Oshida	Vice President, Medical Science, Japan Medical Affairs	Vice President, Clinical Development 3, Development
Keita Matsui	Vice President, Medical Research, Japan Medical Affairs	Vice President, Medical Affairs
Naoko Sato	Vice President, Medical Information Center, Japan Medical Affairs	Vice President, Medical Information Center
Hideki Shima	Divisional Senior Vice President, Technology Planning & Administration, Technology	President, Astellas Ireland Co., Ltd

Kazutoshi Ban	Vice President, Biotechnology Labs., Technology	Senior Director, Biotechnology Labs., Technology
Tadashi Hakomori	Divisional Senior Vice President, Pharmaceutical Research & Technology Labs., Technology	Senior Director, Yaizu Technology Center, Astells Pharma Tech Co., Ltd.
Katsumi Ozawa	General Manager, Tokyo Branch, Japan Sales & Marketing	General Manager, Kyusyu Branch, Japan Sales & Marketing
Atsuhito Iizumi	General Manager, Kobe Branch, Japan Sales & Marketing	Executive Director, Yokohama Branch, Japan Sales & Marketing
Kazuhiko Hayashida	General Manager, Chugoku Branch, Japan Sales & Marketing	Executive Director, Kyoto Branch, Japan Sales & Marketing
Kouji Ohba	General Manager, Kyusyu Branch, Japan Sales & Marketing	General Manager, Chugoku Branch, Japan Sales & Marketing
Junko Komatsu	Vice President, Marketing & Business Management, Asia/Oceania Business	Executive Director, Product Marketing, Japan Sales & Marketing
Yukio Matsui	Senior Vice President, Global Marketing Strategy	Vice President, Marketing & Business Management, Asia/Oceania Business

8. Personnel Changes of Affiliates effective on April 1, 2015

Name	New Title	Current Title
Kazuhiro Sako	President, Astellas Ireland Co., Ltd	Divisional Senior Vice President, Pharmaceutical Research & Technology Labs., Technology
Charlotte Kremer	Executive Vice President, Medical Affairs Astellas Pharma Global Development, Inc.	Senior Vice President, Global Medical Affairs, Astellas Pharma Global Development, Inc.
Bernie Zeiher	President, Global Development, Astellas Pharma Global Development, Inc.	Therapeutic Area Head and Executive Vice President, Global Development Astellas Pharma Global Development, Inc.

9. Appointment of Staff Executive Director of Astellas Pharma Inc. effective on April 1, 2015

Name	New Title	Current Title
Shinya Yano	Staff Executive Director, Product and Portfolio Strategy	Executive Director, Product and Portfolio Strategy
Shigenori Kawasaki	Staff Executive Director, Clinical Development Administration, Japan/Asia Development	Vice President, Clinical Development 1, Development
Junichiro Honda	Staff Executive Director, Human Resources Development, Japan Sales & Marketing	Executive Director, Human Resources Development, Japan Sales & Marketing

10. Organization Changes

Medical Affairs

In order to strengthen medical functions and organization management in Japan, Medical Affairs Division will be newly established and structuralize existing Medical Affairs and Medical Information. The names of Medical Affairs and Medical Information will change respectively to “Medical Science” and “Medical Information Center”. In addition, the functions of Post-marketing Clinical Trial and Post-marketing Survey currently under Medical Affairs will move to under Medical Affairs Division, as newly established “Medical Research”.

Pharma Breakthrough

The name of Pharma Breakthrough will change to “Evolving Medical Solutions”. The new department name will enforce to reflect the department mission, collaborating with medically and pharmaceutically relevant field and providing the patients with breakthrough solutions.

Regenerative Medicine Labs.

The initial objective of Regenerative Medicine Unit established in April 2014 has been achieved. In order to reinforce research function to evaluate the regenerative medicine programs for clinical studies and in order to create a structure capable for more efficiently and effectively managing external collaboration with regenerative medicine-related authorities etc. as well as internal collaboration, the existing Regenerative Medicine Unit will be reorganized as a new organization named “Regenerative Medicine Labs”.

Drug Repurposing & Application Management

Drug Repurposing & Application Management will be created as a new organization which will take a central role in maximization of the outcomes from drug repurposing activities conducted in Drug Discovery Research and appropriate management of research quality assurance in external collaborations as well as internal research in Drug Discovery Research.

Clinical Development

In order to strengthen clinical development functions for global strategic alignment including Asian countries and enabling higher mobility and flexible resource management, Clinical Development 1-3 and Asia Development restructured into “Japan/ Asia Clinical Development 1 and 2”.

###

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201, FAX:+81-3-5201-7473 http://www.astellas.com/en